A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout
Status:
Not yet recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to confirm the efficacy of dotinurad 4 milligram (mg) to
febuxostat 40 mg on the percentage of participants achieving a serum uric acid (SUA) level
less than or equal to (<=) 6.0 milligrams per deciliter (mg/dL) at Week 24 in Chinese
participants with gout.